Detection of liver metastases from pancreatic cancer using FDG PET
- PMID: 10025831
Detection of liver metastases from pancreatic cancer using FDG PET
Abstract
We evaluated the potential of the glucose analog [18F]fluorodeoxyglucose (FDG) as a PET tracer for the hepatic staging in 168 patients designated for resective pancreatic surgery.
Methods: Metastatic liver disease was confirmed or excluded during surgery or with CT follow-up for at least 6 mo. Proven metastases were then retrospectively identified on preoperative CT (gold standard). Hepatic PET scans of all patients were interpreted blindly. Any focal FDG uptake was considered malignant. Both proven hepatic metastases and suspicious hepatic PET lesions were then compared, lesion by lesion, with CT. Standardized uptake values (SUV) and tumor-to-liver ratios (T/L) were determined for the most intense lesion of each patient.
Results: Sensitivity of FDG PET was 68% (15 of 22 patients). The lesion detection rate was 97% (28 of 29 metastases) for lesions >1 cm and 43% (16 of 37 metastases) for lesions < or = 1 cm. Specificity was 95% (138 of 146 patients). Six of eight patients with false-positive results had marked intrahepatic cholestasis (versus 3 of 15 patients with true-positive lesions), one had an infrahepatic abscess and one had a right basal pulmonary metastasis. The SUV and T/L were 4.6+/-1.4 and 2.3+/-1.1, respectively, for malignant lesions and 4.1+/-1.5 and 1.9+/-0.3, respectively, for false-positive lesions and therefore are of limited value.
Conclusion: FDG PET provides reliable hepatic staging for lesions >1 cm. False-positive results are associated with the presence of marked intrahepatic cholestasis. For lesions < or = 1 cm, FDG PET can define malignancy in 43% of suspicious CT lesions in the absence of dilated bile ducts.
Similar articles
-
Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.J Nucl Med. 1999 Nov;40(11):1784-91. J Nucl Med. 1999. PMID: 10565771
-
Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?Acta Gastroenterol Belg. 2007 Oct-Dec;70(4):331-8. Acta Gastroenterol Belg. 2007. PMID: 18330088
-
Contribution of PET in the detection of liver metastases from pancreatic tumours.Clin Radiol. 1999 Apr;54(4):248-52. doi: 10.1016/s0009-9260(99)91160-1. Clin Radiol. 1999. PMID: 10210345
-
Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) --usefulness and limitations in "clinical reality".Ann Nucl Med. 2003 Jun;17(4):261-79. doi: 10.1007/BF02988521. Ann Nucl Med. 2003. PMID: 12932109 Review.
-
FDG PET/CT in the liver: lesions mimicking malignancies.Abdom Imaging. 2014 Feb;39(1):187-95. doi: 10.1007/s00261-013-0043-3. Abdom Imaging. 2014. PMID: 24233161 Review.
Cited by
-
Challenges of Pancreatic Cancer.Cancer J. 2015 May-Jun;21(3):188-93. doi: 10.1097/PPO.0000000000000109. Cancer J. 2015. PMID: 26049698 Free PMC article. Review.
-
The incremental value of dual modality PET/CT imaging over PET imaging alone in advanced colorectal cancer.Indian J Surg. 2009 Apr;71(2):63-8. doi: 10.1007/s12262-009-0018-3. Epub 2009 May 2. Indian J Surg. 2009. PMID: 23133117 Free PMC article.
-
[PET and PET-CT of malignant tumors of the exocrine pancreas].Radiologe. 2009 Feb;49(2):131-6. doi: 10.1007/s00117-008-1756-0. Radiologe. 2009. PMID: 19219476 Review. German.
-
Staging cancer of the pancreas.Cancer Imaging. 2010 Oct 4;10 Spec no A(1A):S137-41. doi: 10.1102/1470-7330.2010.9028. Cancer Imaging. 2010. PMID: 20880783 Free PMC article. Review.
-
Utility of 18F-FDG PET with a semi-quantitative index in the detection of sarcomatous transformation in patients with neurofibromatosis type 1.PLoS One. 2014 Feb 6;9(2):e85954. doi: 10.1371/journal.pone.0085954. eCollection 2014. PLoS One. 2014. PMID: 24516522 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical